Reaction
Urine Output Increased reporting signals
As of the last recalculation, Urine Output Increased appears in 2,592 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is CANAGLIFLOZIN (PRR 70.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Canagliflozin | 239 | 70.6 | 71.1 |
| Teduglutide | 79 | 48.5 | 48.8 |
| Tolvaptan | 46 | 25.9 | 25.9 |
| Mirabegron | 52 | 11.0 | 11.0 |
| Valsartan And Hydrochlorothiazide | 16 | 9.5 | 9.5 |
| Alpelisib | 10 | 9.2 | 9.3 |
| Lithium Carbonate | 17 | 8.1 | 8.1 |
| Empagliflozin | 65 | 7.9 | 7.9 |
| Cortisone Acetate | 11 | 7.2 | 7.2 |
| Fesoterodine Fumarate | 9 | 6.7 | 6.7 |
| Valproate Sodium | 17 | 6.6 | 6.6 |
| Abaloparatide | 23 | 6.3 | 6.3 |
| Loperamide Hydrochloride Oral | 8 | 6.3 | 6.3 |
| Nebivolol | 12 | 6.1 | 6.1 |
| Sitagliptin And Metformin Hydrochloride | 16 | 6.0 | 6.0 |
| Eplerenone | 9 | 5.7 | 5.7 |
| Nebivolol Hydrochloride | 22 | 5.3 | 5.3 |
| Doxazosin | 18 | 5.2 | 5.2 |
| Loperamide Hcl | 8 | 5.0 | 5.0 |
| Glimepiride | 21 | 4.4 | 4.4 |
| Lanreotide Acetate | 4 | 4.1 | 4.1 |
| Sacubitril And Valsartan | 58 | 4.1 | 4.1 |
| Vibegron | 4 | 4.0 | 4.0 |
| Lacosamide | 17 | 3.7 | 3.7 |
| Relugolix | 10 | 3.4 | 3.4 |
| Deferasirox | 11 | 3.3 | 3.3 |
| Dofetilide | 4 | 3.1 | 3.1 |
| Asenapine Maleate | 3 | 2.8 | 2.8 |
| Paliperidone | 8 | 2.8 | 2.8 |
| Apalutamide | 4 | 2.7 | 2.7 |
| Abiraterone Acetate | 13 | 2.5 | 2.5 |
| Varenicline Tartrate | 18 | 1.8 | 1.8 |
| Esketamine Hydrochloride | 4 | 1.8 | 1.8 |
| Paliperidone Palmitate | 7 | 1.7 | 1.7 |
| Dulaglutide | 18 | 1.6 | 1.6 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 6 | 1.6 | 1.6 |
| Nirmatrelvir And Ritonavir | 8 | 1.2 | 1.2 |
| Pimavanserin Tartrate | 6 | 0.9 | 0.9 |